ReviewLancet (London, England)2024
B-cell non-Hodgkin lymphomas.
Review in Lancet (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Meta-analysis of comparing CAR-T and bispecific antibody therapy in relapsed/refractory indolent B-cell non-Hodgkin's lymphomas.Journal of translational medicine · 2025Pooled it
- Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.Nature cancer · 2025Trial
- Simultaneous DOTATATE uptake in three non-neuroendocrine pathologies: Follicular lymphoma, Crohn's disease, and vertebral hemangioma.Radiology case reports · 2026Article
- Quality and Safety Intervention: Improving Care of Patients Undergoing B Cell-Targeted Therapies.The journal of allergy and clinical immunology. In practice · 2026Article
- PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.European journal of nuclear medicine and molecular imaging · 2026Article
- Follicular Lymphoma Arising in an Ileal Neobladder Presenting as a Large Pelvic Mass.IJU case reports · 2026Article
- Identification of Discriminatory Factors and Construction of a Nomogram for Differentiating IgG4-RD and DLBCL.Immunity, inflammation and disease · 2026Article
- Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma.Molecular cancer therapeutics · 2026Review
- Article
- High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma.Nature communications · 2026Article
- Rituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell-Activating Properties in B Cell Lymphoma.Journal of extracellular vesicles · 2026Article
- SOX5 Orchestrates Malignant Evolution via Promoter-Centric Chromatin Remodeling in MYC-Driven B-Cell Lymphoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Histologic Diagnosis of Intravascular Large B-Cell Lymphoma After Endovascular Thrombectomy: A Case Report of a Rare and Incidental Finding.Reports (MDPI) · 2026Article
- A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen.Journal of clinical medicine · 2026Article
- Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs-STAT3 Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Safety evaluation of CD3×CD20 bispecific antibodies: a pharmacovigilance study using FDA adverse event reporting system.BMJ open · 2026Article
- Novel therapeutic targets at the crossroad between epigenetics and signal transduction pathways in B-cell lymphomas.Clinical and experimental medicine · 2026Review
- Exosomes liquid biopsy in Lymphoma precision medicine: applications and challenges.Cancer cell international · 2026Review
- Article
- A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.Oncology and therapy · 2026Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. They can affect any organ and are characterised by heterogeneous clinical presentations and courses, varying from asymptomatic, to indolent, to very aggressive cases. Since the topic of B-cell non-Hodgkin lymphomas was last reviewed in The Lancet in 2017, a deeper understanding of the biological background of this heterogeneous group of malignancies, the availability of new diagnostic methods, and the development and implementation of new targeted and immunotherapeutic approaches have improved our ability to treat patients. This Seminar provides an overview of the pathobiology, classification, and prognostication of B-cell non-Hodgkin lymphomas and summarises the current knowledge and standard of care regarding biology and clinical management of the most common subtypes of mature B-cell non-Hodgkin lymphomas. It also highlights new findings in deciphering the molecular background of disease development and the implementation of new therapeutic approaches, particularly those targeting the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.